Bristol-Myers Squibb Co. info
June 8 2016
FDA approves Bristol Myers Squibb's Opdivo for lung cancer
Bristol Myers Squibb drugs
ATRIPLA (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) Tablets
Baraclude (entecavir) - In August of 2007, Bristo Myers warned patients co-infected with both the hepatitis B and the human immunodeficiency virus (HIV) that they should not take Baraclude unless they are also being treated with the standard anti-retroviral therapy. Resistance to the HIV virus can develop if a patient is not being treated for HIV
Cardiolite (kit for the preparation of
Technetium Tc99m Sestamibi for injection)
ConvaTec Ostomy Care
ConvaTec Wound Therapeutics
EMSAM (selegiline transdermal system)
Enfamil (infant formula)
Plavix (clopidogrel bisulfate)
Pravachol (pravastatin sodium) Tablets
Reyataz (atazanavir sulfate)
SPRYCEL (dasatinib) Tablets - Bristol-Myers Squibb Co. says results of a late-stage trial showed patients did just as well on a lower-than-standard dose of its leukemia drug Sprycel and had fewer side effects.
TAXOL (paclitaxel) Injection
Videx EC (didanosine, delayed-release capsules)
2006 - Bristol-Myers Squibb had third-quarter
earnings in 2006 plunge as sales of the anti-clotting drug Plavix were hurt by a
cheaper generic. New York-based Bristol earned $338 million, or 17 cents per
share, from continuing operations, compared with $964 million, or 49 cents per
share, in the year-ago quarter. Plavix was hurt by competition from the early
introduction of the cheaper generic by privately held Canadian drug maker Apotex
Inc. A deal between Bristol-Myers and Apotex to delay the generic for years fell
apart and is now under criminal investigation by the U.S. government for
possible antitrust violations. The probe has been widened to review whether the
deal violated federal securities laws. Plavix, used to prevent blood clots that
can trigger heart attacks, was the world's second-biggest medicine, with global
annual sales of $6 billion before the generic arrived.
Global sales of hypertension drug Avapro, sold with Sanofi-Aventis, rose 10 percent to $277 million.
Revenue from schizophrenia treatment Abilify jumped 20 percent to $313 million.
Reyataz, a once-daily protease inhibitor against HIV whose use expanded sharply outside the United States, rose 32 percent to $233 million.
Sales of Erbitux, marketed in partnership with ImClone Systems Inc. for colon cancer and head and neck cancer, jumped 64 percent to $175 million.